Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1805370 | 0.87 | POLB (0.43) | ALDH1A1POLB | |
| SCHEMBL1805372 | 0.87 | POLB (0.43) | ALDH1A1POLB | |
| SCHEMBL861580 | 0.87 | POLB (0.43) | ALDH1A1POLB | |
| SCHEMBL860406 | 0.86 | MAPKAPK2 (0.41) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL860405 | 0.86 | MAPKAPK2 (0.41) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL1807470 | 0.84 | MEN1 (0.34) | POLB | |
| SCHEMBL1807469 | 0.84 | MEN1 (0.34) | POLB | |
| SCHEMBL852105 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPK14ADRA1B | |
| SCHEMBL852106 | 0.82 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2MAPK14ADRA1B | |
| SCHEMBL860900 | 0.82 | MAPKAPK2 (0.46) | ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | claimed |
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2016-04-07 | — | — | US | claimed |
| US-9187483-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2015-11-17 | — | — | US | claimed |
| EP-2641907-B1 | Preparation of modulators of 5-HT receptors | ABBVIE INC (US) | 2015-01-28 | — | — | EP | claimed |
| EP-2641907-A1 | Preparation of modulators of 5-HT receptors | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2432783-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2013-05-01 | — | — | EP | claimed |
| EP-2571353-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Inc. (US) | 2013-03-27 | — | — | EP | claimed |
| EP-2432783-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2012-03-28 | — | — | EP | claimed |
| WO-2011146089-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | WO | claimed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | claimed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | claimed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | claimed |
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-12-06 | — | — | US | disclosed |
| US-9879033-B2 | Modulators of 5-HT receptors and methods of use thereof | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-30 | — | — | US | disclosed |
| EP-2571353-B1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2011146089-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2010135560-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096851-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CASP3 1672/4885ALDH1A1 971/4885SMN1; SMN2 4775/4885 |
| US-20100298292-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CASP3 1672/4885ALDH1A1 971/4885SMN1; SMN2 4775/4885 |
| US-20110118231-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CASP3 1672/4885ALDH1A1 971/4885SMN1; SMN2 4775/4885 |
| US-20180346484-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR3A, HTR5A, HTR3C | CASP3 1672/4885ALDH1A1 971/4885SMN1; SMN2 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.